Dr George Ngondi: The Scientist Who Bet KSh454 Million on a DNA Dream

Equity Bank’s asset-backed financing helped Nextgen Molecular Lab acquire advanced genomic sequencing technology, expanding Kenya’s capacity for precision medicine.

When Dr George Ngondi set out to build a genomics laboratory capable of high-throughput genetic sequencing in Kenya, he knew the science would be demanding. However, securing the financing for the technology proved just as challenging.

Ngondi, a microbiologist and genomics expert, is the founder and director of Nextgen Molecular Lab. The facility conducts molecular and genomic testing to help diagnose diseases and understand them through the analysis of genetic material.

To establish its advanced sequencing capability, the laboratory needed about US$3.5 million, equivalent to approximately KSh454 million. Finding a lender willing to support such a specialized investment became one of his biggest hurdles.

“We approached many banks, and everywhere we went, we faced a lot of challenges. So, we had to go for debt financing, and debt financing was a bigger challenge,” said Ngondi.

A KSh454 Million Investment in Genomic Science

The investment went beyond the sequencing machine itself. Before acquiring the main equipment, Ngondi had already invested more than KSh100 million in laboratory infrastructure and supporting equipment.

This included a negative-pressure room for DNA isolation, PCR machines, quality-control analyzers and equipment for library preparation. These facilities help prepare biological samples for analysis and support the laboratory’s operations.

The additional investment highlights the cost of establishing a specialized genomics facility. Beyond buying advanced equipment, providers must also build the infrastructure needed to operate it properly.

At the centre of Nextgen’s investment is the NovaSeq™ System, an ultra-high-throughput Next-Generation Sequencing platform. It can process large volumes of genetic material, allowing scientists to analyze DNA on a much greater scale.

How DNA Sequencing Can Support Better Healthcare

DNA contains genetic information that helps scientists understand how living organisms function. By analyzing this information, researchers can identify genetic changes associated with certain diseases and investigate how those diseases develop.

For example, genomic sequencing can help researchers study genetic variations and drug resistance. It can also support investigations into why patients respond differently to particular medicines.

This knowledge contributes to the development of precision medicine, an approach that considers a patient’s biological characteristics when informing healthcare decisions.

For Nextgen, the NovaSeq™ System provides the capacity to process large volumes of genetic material locally. The information generated can support research, clinical investigations and work aimed at improving understanding of disease.

Ngondi believes that understanding a person’s genetic makeup can help inform healthcare decisions.

“What I tell people is that you are your DNA, and your DNA is you. So, if you know your DNA, you know your blueprint,” he said.

He added that genetic information can support more informed decisions about treatment.

“Trust me, we need to know ourselves so that we can make better decisions, more informed decisions, and have more precision when it comes to the medications we choose,” he said.

How Equity Bank Helped Unlock the Investment

For Ngondi, acquiring the sequencing system required a financing structure that recognized the value of the equipment itself.

The breakthrough came when Equity Bank structured the financing around the genetic sequencer. Instead of relying on conventional collateral such as land, the instrument itself supported the financing arrangement.

“The instrument was used as collateral. We did not have to give a title deed as collateral, and we are talking about a total of US$3.5 million,” said Ngondi.

The financing also included safeguards for the specialized equipment. Illumina, the system’s supplier, provided a warranty and service contract to help mitigate equipment-related risks.

This arrangement enabled Nextgen Molecular Lab to acquire the NovaSeq™ System, which the laboratory describes as the only one of its kind in East and Central Africa.

The system strengthens regional capacity for high-throughput genomic sequencing. It also creates opportunities to conduct more advanced genomic research locally and support work in precision medicine.

Dr George Ngondi: The Scientist Who Bet KSh454 Million on a DNA Dream

Financing Specialized Healthcare Equipment

The investment illustrates a challenge facing many healthcare businesses: the high cost of acquiring specialized equipment.

Diagnostic laboratories, imaging centres, dialysis units, dental and optical clinics, and specialized oncology and cardiology facilities all require substantial capital to establish or expand their services.

However, conventional collateral requirements can make it difficult for providers to secure financing for expensive equipment.

Dr Joseph Mbai EBS, General Manager and Team Leader for Health Sector at Equity Bank Kenya, said financing can help healthcare providers acquire equipment that would otherwise remain beyond their reach.

“Healthcare providers need access to the right equipment to offer quality services. When financing constraints prevent them from acquiring that equipment, it ultimately limits the services they can provide. Our role as Equity Bank is to help bridge that gap by making it possible for healthcare providers such as Nextgen Molecular Lab to invest in the equipment they need without looking for traditional collateral such as a title deed,” said Mbai.

Asset-backed financing can therefore provide an alternative for specialized businesses seeking to invest in equipment. The structure allows the financing arrangement to reflect the asset being acquired, subject to the lender’s assessment and terms.

Building Kenya’s Genomics Capacity

Nextgen Molecular Lab is now engaging in large-scale projects involving hospitals, research institutions and patient populations.

These engagements could help expand the use of genomic sequencing in research and clinical investigations. However, translating advanced technology into wider healthcare benefits also depends on collaboration, appropriate clinical applications and access to expertise.

For Ngondi, the journey from struggling to secure capital to establishing an advanced sequencing platform demonstrates the importance of financing that reflects the needs of specialized businesses.

The machine is the visible outcome of the investment. Behind it lies a wider ambition: to build advanced genomic capabilities locally, strengthen disease research and support more informed healthcare decisions.

The experience also highlights how financing can influence innovation. When lenders find ways to support specialized equipment investments, healthcare enterprises can pursue technologies that might otherwise remain out of reach.